donate now The Fatty Liver Foundation


Viking Therapeutics has been a key player in the development of novel therapeutics for metabolic and endocrine disorders, with their investigational drug VK2809 standing out as a significant advancement in the treatment of Nonalcoholic Steatohepatitis (NASH). This paper provides an overview of VK2809, detailing its clinical development, regulatory milestones, and the implications of its success in recent studies.

**Introduction to VK2809**

VK2809 is a liver-selective thyroid hormone receptor beta (THR-β) agonist developed by Viking Therapeutics. It targets liver tissue to reduce hepatic fat content and improve liver health markers in patients with NASH. By modulating lipid metabolism pathways selectively, VK2809 aims to offer significant therapeutic benefits in NASH without the systemic side effects associated with thyroid hormone therapy.

**Clinical Development and Trials**

The VOYAGE study, a Phase 2b clinical trial, was initiated by Viking Therapeutics in November 2019 to assess the efficacy, safety, and tolerability of VK2809 in patients with biopsy-confirmed NASH and fibrosis. This randomized, double-blind, placebo-controlled, multicenter international trial is designed to provide critical data on VK2809's potential as a therapeutic option for NASH patients [1].

**Regulatory Milestones**

A critical milestone for VK2809 was reached with the completion of enrollment in the Phase 2b VOYAGE study. This achievement underscores Viking Therapeutics' commitment to advancing the clinical development of VK2809 and highlights the significant interest within the medical community in exploring novel treatments for NASH, a condition that currently has limited therapeutic options [2].

**Recent Data and Implications**

At The Liver Meeting® 2023, new data from the Phase 2b VOYAGE study were presented, showcasing VK2809's potential in treating patients with biopsy-confirmed NASH. While specific results were not detailed here, the presentation of new data at such a prestigious conference indicates positive progress in VK2809's clinical development journey and its potential impact on NASH treatment paradigms [3].

**Preclinical Success**

In addition to its clinical trials, VK2809 has demonstrated potent reductions in plasma and liver lipids, as well as improvements in liver fibrosis in a rodent model of diet-induced NASH. VK2809-treated rodents also showed improvement in genes associated with lipid metabolism and suppression of genes associated with fibrogenic signaling, further supporting its potential efficacy in treating NASH [4].


1. Viking Therapeutics. (2019). "Viking Therapeutics Initiates VOYAGE Study for VK2809." [Online]. Available:
2. Viking Therapeutics. (2023). "Viking Therapeutics Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)." [Online]. Available:
3. Viking Therapeutics. (2023). "Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2023." [Online]. Available:
4. Viking Therapeutics. "Metabolic Disease Programs - Preclinical Data on VK2809." [Online]. Available:

This compilation of references details the journey of VK2809 from its inception through clinical trials to recent presentations of data, highlighting its potential as a novel therapeutic option for NASH.